1 May 2024 false No description of principal activity Taxfiler 2024.6 12568106 business:PrivateLimitedCompanyLtd 2024-05-01 2025-04-30 12568106 2024-04-30 12568106 2024-05-01 2025-04-30 12568106 business:AuditExemptWithAccountantsReport 2024-05-01 2025-04-30 12568106 business:FilletedAccounts 2024-05-01 2025-04-30 12568106 2025-04-30 12568106 business:Director1 2024-05-01 2025-04-30 12568106 business:RegisteredOffice 2024-05-01 2025-04-30 12568106 2024-04-30 12568106 core:WithinOneYear 2025-04-30 12568106 core:WithinOneYear 2024-04-30 12568106 core:ShareCapital core:PreviouslyStatedAmount 2025-04-30 12568106 core:ShareCapital core:PreviouslyStatedAmount 2024-04-30 12568106 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-04-30 12568106 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2024-04-30 12568106 core:PreviouslyStatedAmount 2025-04-30 12568106 core:PreviouslyStatedAmount 2024-04-30 12568106 business:SmallEntities 2024-05-01 2025-04-30 12568106 countries:EnglandWales 2024-05-01 2025-04-30 12568106 core:FurnitureFittings 2024-04-30 12568106 core:FurnitureFittings 2025-04-30 12568106 core:FurnitureFittings 2024-05-01 2025-04-30 12568106 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure
Company Registration No. 12568106 (England and Wales)
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Unaudited accounts for the year ended 30 April 2025
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Unaudited accounts Contents
Page
Company information
3
Accountants' report
4
Statement of financial position
5
Notes to the accounts
6
- 2 -
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Company Information for the year ended 30 April 2025
Director
mohammad amin mohammad
Company Number
12568106 (England and Wales)
Registered Office
FLAT 1 32 PEMBERTON DRIVE BRADFORD BD7 1RA ENGLAND
Accountants
AK ACCOUNTANTS 562-564 MANCHESTER ROAD BRADFORD WEST YORKSHIRE BD5 7LR
- 3 -
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Accountants' report
Accountants' report to the director of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD on the preparation of the unaudited statutory accounts for the year ended 30 April 2025
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD for the year ended 30 April 2025 as set out on pages 5 - 7 from the company's accounting records and from information and explanations you have given us.
This report is made solely to the Board of Directors of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD, as a body, in accordance with the terms of our engagement letter dated 26 June 2021. Our work has been undertaken solely to prepare for your approval the accounts of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD and state those matters that we have agreed to state to them, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and loss of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD. You consider that SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
AK ACCOUNTANTS 562-564 MANCHESTER ROAD BRADFORD WEST YORKSHIRE BD5 7LR 12 May 2025
- 4 -
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Statement of financial position as at 30 April 2025
2025
2024
Notes
£
£
Fixed assets
Tangible assets
4
1,204
1,463
Current assets
Cash at bank and in hand
802
3,492
Creditors: amounts falling due within one year
5
(7,299)
(4,360)
Net current liabilities
(6,497)
(868)
Net (liabilities)/assets
(5,293)
595
Capital and reserves
Called up share capital
1
1
Profit and loss account
(5,294)
594
Shareholders' funds
(5,293)
595
For the year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 12 May 2025 and were signed on its behalf by
mohammad amin mohammad Director Company Registration No. 12568106
- 5 -
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Notes to the Accounts for the year ended 30 April 2025
1
Statutory information
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD is a private company, limited by shares, registered in England and Wales, registration number 12568106. The registered office is FLAT 1, 32 PEMBERTON DRIVE, BRADFORD, BD7 1RA, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
4
Tangible fixed assets
Fixtures & fittings
£
Cost or valuation
At cost
At 1 May 2024
2,507
At 30 April 2025
2,507
Depreciation
At 1 May 2024
1,044
Charge for the year
259
At 30 April 2025
1,303
Net book value
At 30 April 2025
1,204
At 30 April 2024
1,463
5
Creditors: amounts falling due within one year
2025
2024
£
£
Taxes and social security
117
117
Loans from directors
6,462
3,573
Accruals
720
670
7,299
4,360
- 6 -
SCIENCE DEVELOPMENT & RESEARCH PHARMA LTD Notes to the Accounts for the year ended 30 April 2025
6
Average number of employees
During the year the average number of employees was 1 (2024: 1).
- 7 -